Biosimilar ABP 710 vs Infliximab Reference Product in RA Biosimilar ABP 710 vs Infliximab Reference Product in RA

Might this new biosimilar be a viable treatment option for patients with rheumatoid arthritis? How does it compare with infliximab reference product?Arthritis Research & Therapy
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news